On Friday, Travere Therapeutics Inc (NASDAQ: TVTX) was -4.78% down from the session before settling in for the closing price of $6.69. A 52-week range for TVTX has been $5.25 – $22.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 3.07%. When this article was written, the company’s average yearly earnings per share was at -96.83%. With a float of $75.03 million, this company’s outstanding shares have now reached $75.37 million.
Let’s determine the extent of company efficiency that accounts for 380 employees.
Travere Therapeutics Inc (TVTX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Travere Therapeutics Inc stocks. The insider ownership of Travere Therapeutics Inc is 1.41%, while institutional ownership is 113.82%. The most recent insider transaction that took place on Apr 11 ’24, was worth 364. In this transaction CHIEF FINANCIAL OFFICER of this company sold 54 shares at a rate of $6.74, taking the stock ownership to the 70,849 shares. Before that another transaction happened on Feb 01 ’24, when Company’s CHIEF EXECUTIVE OFFICER sold 19,122 for $8.70, making the entire transaction worth $166,435. This insider now owns 350,600 shares in total.
Travere Therapeutics Inc (TVTX) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2023, it has been observed that the corporation posted -$1.18 earnings per share (EPS) during the time that was better than consensus figure (set at -$1.27) by $0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -96.83% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
You can see what Travere Therapeutics Inc (TVTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.56, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -1.83 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Looking closely at Travere Therapeutics Inc (NASDAQ: TVTX), its last 5-days average volume was 1.65 million, which is a jump from its year-to-date volume of 1.25 million. As of the previous 9 days, the stock’s Stochastic %D was 15.29%. Additionally, its Average True Range was 0.45.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 17.02%, which indicates a significant increase from 6.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.02% in the past 14 days, which was lower than the 70.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.83, while its 200-day Moving Average is $9.89. However, in the short run, Travere Therapeutics Inc’s stock first resistance to watch stands at $6.63. Second resistance stands at $6.89. The third major resistance level sits at $7.08. If the price goes on to break the first support level at $6.18, it is likely to go to the next support level at $5.99. Should the price break the second support level, the third support level stands at $5.73.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
There are 76,109K outstanding shares of the company, which has a market capitalization of 484.76 million. As of now, sales total 145,240 K while income totals -111,400 K. Its latest quarter income was 37,100 K while its last quarter net income were 150,740 K.
